Basic science and clinical aspects of vascular anomalies

Current Opinion in Pediatrics

Volumn 17, Issue 4, 2005, Pages 501-509

  Blei, Francine ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Genetic mutations; Lymphatic anomalies; Prevention strategy; Risk stratification; Susceptibility genes; Targeted therapy; Vascular anomalies; Vascular development

Indexed keywords

CORTICOSTEROID; FC RECEPTOR; GLUCOSE TRANSPORTER 1; MEROSIN; PREDNISOLONE; SOMATOMEDIN; STEROID; VINCRISTINE;

ADRENAL SUPPRESSION; ANGIOGENESIS; ANGIOMA; ANGIOOSTEOHYPERTROPHY SYNDROME; BONE GROWTH; BONE MINERALIZATION; CANCER MORTALITY; CONGENITAL BLOOD VESSEL MALFORMATION; CUTIS MARMORATA TELANGIECTATICA CONGENITA; CYSTIC LYMPHANGIOMA; GENE EXPRESSION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEMANGIOMA; HEMANGIOPERICYTOMA; HUMAN; HYPERTENSION; KASABACH MERRITT SYNDROME; LYMPHANGIOMA; NEVUS FLAMMEUS; PNEUMONIA; PRIORITY JOURNAL; PYOGENIC GRANULOMA; REVIEW; SIDE EFFECT; VASCULAR TUMOR;

HEMANGIOMA; HUMANS; INFANT, NEWBORN; SKIN DISEASES, VASCULAR; SKIN NEOPLASMS;

EID: 23344454905     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000171322.76429.80     Document Type: Review

References (76)

1. Folkman J. Toward a new understanding of vascular proliferative disease in children. Pediatrics 1984; 74:850.
2. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982; 69:412-422.
3. Chang MW. Updated classification of hemangiomas and other vascular anomalies. Lymphat Res Biol 2003; 1:259-265.
4. Ritter M, Dorrell M, Edmonds J, et al. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci USA 2002; 99:7455.
5. Ritter M, Moreno S, Dorrell M, et al. Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution. Lymphat Res Biol 2003; 1:291.
6. Walter J, North P, Waner M, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 2002; 33:295.
7. Boye E, Yu Y, Paranya G, et al. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001; 107:745.
8. Burton BK, Schulz CJ, Angle B, et al. An increased incidence of haemangiomas in infants born following chorionic villus sampling (CVS). Prenat Diagn 1995; 15:209.
9. Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100:1377.
10. Bree AF, Siegfried E, Sotelo-Avila C, et al. Infantile hemangiomas: speculation on placental trophoblastic origin. Arch Dermatol 2001; 137:573.
11. North P, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31:11-22;
12. North P, Waner M, Mizeracki A, et al. Hum Pathol 2000; 31:11.
13. Mo JQ, Dimashkieh HH, Bove KE. GLUT1 endothelial reactivity distinguishes hepatic infantile hemangioma from congenital hepatic vascular malformation with associated ca2pillary proliferation. Hum Pathol 2004; 35:200. This paper describes new theories regarding hemangioma evolution.
14. Kleinman M, Tepper O, Capla J, et al. Increased circulating AC133+ CD34+ endothelial progenitor cells in children with hemangioma. Lymphat Res Biol 2003; 1:301.
15. Yu Y, Flint AF, Mulliken JB, et al. Endothelial progenitor cells in infantile hemangioma. Blood 2004; 103:1373.
16. Nguyen VA, Furhapter C, Romani N, et al. Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology. Hum Pathol 2004; 35:739.
17. Dadras SS, North PE, Bertoncini J, et al. Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod Pathol 2004; 17:1068. This well-designed study analyzes the properties of hemangioma cells and postulates novel theories.
18. Tan ST, Wallis RA, He Y, et al. Mast cells and hemangioma. Plast Reconstr Surg 2004; 113:999. According to the findings of this paper, mast cells and other cellular elements are likely involved with different stages of hemangioma development.
19. Frischer JS, Huang J, Serur A, et al. Biomolecular markers and involution of hemangiomas. J Pediatr Surg 2004; 39:400.
20. Lyons LL, North PE, Mac-Moune Lai F, et al. Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol 2004; 28:559.
21. Sanchez-Carpintero I, Mihm MC, Mizeracki A, et al. Epithelial and mesenchymal hamartomatous changes in a mature port-wine stain: morphologic evidence for a multiple germ layer field defect. J Am Acad Dermatol 2004; 50:608.
22. Gordillo GM, Onat D, Stockinger M, et al. A key angiogenic role of monocyte chemoattractant protein-1 in hemangioendothelioma proliferation. Am J Physiol Cell Physiol 2004; 287:C866-C873.
23. Rothermel TA, Engelhardt B, Sheibani N. Polyoma virus middle-T-transformed PECAM-1 deficient mouse brain endothelial cells proliferate rapidly in culture and form hemangiomas in mice. J Cell Physiol 2005; 202:230.
24. Sun JF, Phung T, Shiojima I, et al. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci USA 2005; 102:128.
25. Krebs LT, Shutter JR, Tanigaki K, et al. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev 2004; 18:2469.
26. Happle R. Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. J Am Acad Dermatol 1987; 16:899.
27. Tille J, Pepper M. Hereditary vascular anomalies: new insights into their pathogenesis. Arterioscler Thromb Vasc Biol 2004; 24:1578. This thorough review bridges basic developmental and clinical genetic information in vascular anomalies.
28. Timur AA, Sadgephour A, Graf M, et al. Identification and molecular characterization of a de novo supernumerary ring chromosome 18 in a patient with Klippel-Trenaunay syndrome. Ann Hum Genet 2004; 68:353.
29. Whelan AJ, Watson MS, Porter FD, et al. Klippel-Trenaunay-Weber syndrome associated with a 5:11 balanced translocation. Am J Med Genet 1995; 59:492.
30. Wang Q, Timur A, Szafranski P, et al. Identification and molecular characterization of de novo translocation t(8;14)(q22.3;q13) associated with a vascular and tissue overgrowth syndrome. Cytogenet Cell Genet 2001; 95: 183.
31. Tian XL, Kadaba R, You SA, et al. Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature 2004; 427:640. Although the relation between VG5Q and angiogenesis/ vasculogenesis and Klippel-Trenauanay syndrome is unclear, the identification of this candidate gene for this disorder is intriguing.
32. Brouillard P, Boon LM, Mulliken JB, et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ('glomangiomas'). Am J Hum Genet 2002; 70:866.
33. Brouillard P, Ghassibe M, Penington A, et al. Four common glomulin mutations cause two thirds of glomuvenous malformations ('familial glomangiomas'): evidence for a founder effect. J Med Genet 2005; 42:e13. This paper demonstrates locus homogeneity in patients with glomovenous malformations and provides support for screening affected patients for these mutations.
34. Boon LM, Mulliken JB, Enjolras O, et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol 2004; 140:971. This excellent presentation of the features differentiating these disorders has clinical relevance.
35. Eerola I, Boon LM, Mulliken JB, et al. Capillary malformation- arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003; 73:1240.
36. Gallione CJ, Repetto GM, Legius E, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363:852. This paper provides further evidence for genotype-phenotype correlations in hereditary hemorrhagic telangiectasia.
37. Fang J, Dagenais SL, Erickson RP, et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 2000; 67:1382.
38. Dagenais SL, Hartsough RL, Erickson RP, et al. Foxc2 is expressed in developing lymphatic vessels and other tissues associated with lymphedema-distichiasis syndrome. Gene Expr Patterns 2004; 4:611.
39. Pransky SM, Canto C. Management of subglottic hemangioma. Curr Opin Otolaryngol Head Neck Surg 2004; 12:509. This paper provides guidelines for the evaluation and management of subglottic hemangiomas.
40. Mathes EFD, Haggstrom AN, Dowd C, et al. Clinical characteristics and management of vascular anomalies: findings of a multidisciplinary vascular anomalies clinic. Arch Dermatol 2004; 140:979. An informative review of a constellation of patients referred to a multidisciplinary vascular anomalies program.
41. Konez O, Burrows PE. An appropriate diagnostic workup for suspected vascular birthmarks. Cleve Clin J Med 2004; 71:505. A helpful review of vascular anomalies from the radiologic perspective.
42. Marler JJ, Mulliken JB. Current management of hemangiomas and vascular malformations. Clin Plast Surg 2005; 32:99. This paper provides guidelines for the evaluation and management of a variety of vascular anomalies.
43. Miller T, Frieden IJ. Hemangiomas: new insights and classification. Pediatr Ann 2005; 34:179. Helpful insights and updates regarding hemangiomas.
44. Rahbar R, Nicollas R, Roger G, et al. The biology and management of subglottic hemangioma: past, present, future. Laryngoscope 2004; 114:1880. Some perspectives for the evaluation and management of subglottic hemangiomas.
45. Bitar MA, Moukarbel RV, Zalzal GH. Management of congenital subglottic hemangioma: trends and success over the past 17 years. Otolaryngol Head Neck Surg 2005; 132:226. Other perspectives for the evaluation and management of subglottic hemangiomas.
46. Bloom DC, Perkins JA, Manning SC. Management of lymphatic malformations. Curr Opin Otolaryngol Head Neck Surg 2004; 12:500. This paper provides guidelines for the evaluation and management of various subtypes of vascular anomalies.
47. Mulliken JB, Enjolras O. Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol 2004; 50:875. This is a helpful review of the subcategories of hemangiomas by authors who are pioneers in this field.
48. Gruman A, Liang MG, Mulliken JB, et al. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon. J Am Acad Dermatol 2005; 52:616. Description of several cases of a subgroup within Kaposiform hemangioendothelioma.
49. North PE, Kahn T, Cordisco MR, et al. Multifocal lymphangioendotheliomatosis with thrombocytopenia: a newly recognized clinicopathological entity. Arch Dermatol 2004; 140:599.
50. Marier JJ, Fishman SJ, Upton J, et al. Prenatal diagnosis of vascular anomalies. J Pediatr Surg 2002; 37:318.
51. Chaft J, Blei F. Prenatal diagnosis of vascular anomalies: update and review of the literature. Lymphat Res Biol 2003; 1:309.
52. Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a 'beard' distribution. J Pediatr 1997; 131:643.
53. Metry DW. Potential complications of segmental hemangiomas of infancy. Semin Cutan Med Surg 2004; 23:107.
54. Metry DW, Hawrot A, Altman C, et al. Association of solitary, segmental hemangiomas of the skin with visceral hemangiomatosis. Arch Dermatol 2004; 140:591. This paper presents important clinical findings based on careful observation.
55. Ceisler E, Blei F. Ophthalmic issues in hemangiomas of infancy. Lymphat Res Biol 2003; 1:321.
56. Sterker I, Grafe G. Periocular hemangiomas in childhood: functional and esthetic results. Strabismus 2004; 12:103.
57. Ceisler EJ, Santos L, Blei F. Periocular hemangiomas: what every physician should know. Pediatr Dermatol 2004; 21:1. This paper clarifies the most important ocular sequelae and proposes guidelines for evaluation.
58. Millischer-Bellaiche AE, Enjolras O, Andre C, et al. Eyelid hemangiomas in infants: contribution of MRI. J Radiol 2004; 85:2019.
59. Kronenberg A, Blei F, Ceisler E, et al. Ocular and systemic manifestations of PHACES (posterior fossa malformations, hemangiomas, arterial anomalies, cardiac defects and coarctation of the aorta, eye abnormalities, and sternal abnormalities or ventral developmental defects) syndrome. J AAPOS 2005; 9:169.
60. Lee A, Driscoll D, Gloviczki P, et al. Evaluation and management of pain in patients with Klippel-Trenaunay syndrome: a review. Pediatrics 2005; 115:744. This paper provides clarification of the most likely causes of pain in this patient group, and proposes guidelines for management.
61. Enjolras O, Chapot R, Merland JJ. Vascular anomalies and the growth of limbs: a review. J Pediatr Orthop B 2004; 13:349. This paper provides insights into orthopedic issues that are important to identify, monitor, and follow up.
62. Scher DM. Orthopedic issues in patients with vascular anomalies. Lymphat Res Biol 2004; 2:51. This paper provides insights into orthopedic issues that are important to identify, monitor, and follow up.
63. Greene AK, Kieran M, Burrows PE, et al. Wilms tumor screening is unnecessary in Klippel-Trenaunay syndrome. Pediatrics 2004; 113:e326.
64. Rebarber A, Roman AS, Roshan D, et al. Obstetric management of Klippel-Trenaunay syndrome. Obstet Gynecol 2005; 104:1205.
65. Greene AK, Rogers GF, Mulliken JB. Management of parotid hemangioma in 100 children. Plast Reconstr Surg 2004; 113:53.
66. Reinisch JF, Kim RY, Harshbarger RJ, et al. Surgical management of parotid hemangioma. Plast Reconstr Surg 2004; 113:1940.
67. Greene AK, Burrows PE, Smith L, et al. Periorbital lymphatic malformation: clinical course and management in 42 patients. Plast Reconstr Surg 2005; 115:22.
68. Fishman SJ, Smithers CJ, Folkman J, et al. Blue rubber bleb nevus syndrome: surgical eradication of gastrointestinal bleeding. Ann Surg 2005; 241:523.
69. Waner M. Novel hemostatic alternatives in reconstructive surgery. Semin Hematol 2004; 41(Suppl 1):163.
70. George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol 2004; 140:963.
71. Aviles R, Boyce TG, Thompson DM. Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas. Mayo Clin Proc 2004; 79:243. This is a humbling report of a potential side effect in a patient treated with oral steroids for a hemangioma.
72. Haisley-Royster C, Enjolras O, Frieden IJ, et al. Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 2002; 24:459.
73. Perez J, Pardo J, Gomez C. Vincristine: an effective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol 2002; 41:197.
74. Perez Payarols J, Pardo Masferrer J, Gomez Bellvert C. Treatment of life-threatening infantile hemangiomas with vincristine. N Engl J Med 1995; 333:69.
75. Enjolras O, Breviere GM, Roger G, et al. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr 2004; 11:99. This report describes a small but important series in which vincristine was used for difficult hemangiomas.
76. Dondon MG, de Vathaire F, Shamsaldin A, et al. Cancer mortality after radiotherapy for a skin hemangioma during childhood. Radiother Oncol 2004; 72:87.